Additional file 5: Table S4. of Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs

Abstract

Rates of reporting normative values for the Health Assessment Questionnaire-Disability Index (HAQ-DI) (≤0.5) per visit; * p ≤0.05, ** p ≤0.01, *** p ≤0.0001 versus placebo. BID twice daily, CI confidence interval on the estimate of the rate. (DOCX 12 kb